A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.

Enrolling by Invitation

Interested in participating?

Key information

Conditions

Chronic HBV Infection Blood-Borne Infections Chronic Disease Communicable Diseases DNA Virus Infections Digestive System Diseases Disease Attributes Hepadnaviridae Infections Hepatitis Hepatitis B Hepatitis B, Chronic Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Virus Diseases

Age range

19 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Queen Mary Hospital, University of Hong Kong, Hong Kong

About this study

This is a LTFU observational study designed to evaluate the safety of PBGENE-HBV in participants previously exposed to PBGENE-HBV. This study protocol does not include administration of PBGENE-HBV.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participant has received at least 1 dose of PBGENE-HBV investigational product in a prior clinical study
Participant, or their legally authorized representative, has provided signed informed consent.

Exclusion criteria

Treatment and study plan

PBGENE-HBV

Biological

PBGENE-HBV is the investigational product administered in the parent study. This LTFU study is non-interventional; no investigational product given.

Primary outcomes

Safety to assess frequency, severity, and outcome of delayed adverse events

Time frame: 15 years

Delayed adverse events

Sponsors and collaborators

Lead sponsor

Precision BioSciences, Inc.

Industry

Registry information

Official study title

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV, an In Vivo Gene Editing Investigational Product, in a Prior Clinical Study

Acronym: ELIMINATE-B

Important dates

Study start: 2025
Primary completion: 2040
Study completion: 2040
First posted: Nov 28, 2025
Registry last updated: Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed